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Through a multicenter study, we collected seven cases of gastric plexiform fibromyxoma
including four females and three males, 21 to 79 y old (46.1  10.1). All cases showed a
unilocular lesion measuring 0.3 to 17 cm (5.3  2.4), arising from antrum (5/7) or body (2/
7). Six of the seven cases had intraoperative frozen sections and/or endoscopic ultra-
sound fine needle aspiration (EUS-FNA), and all of them were preoperatively or intra-
operatively diagnosed as gastrointestinal stromal tumor (GIST). EUS-FNA material
showed markedly elongated spindle cells with streaming oval to elongated nuclei with
rounded ends. Histologically, the tumors exhibited a plexiform growth pattern and were
composed of a rich myxoid stroma and cytologically bland uniform spindle cells without
mitotic figures, with the exception of one case which displayed nuclear pleomorphism
and increased mitosis. Immunostains showed the tumor cells to be focally positive for
SMA (6/6), focally and weakly positive for desmin (3/6) and caldesmon (2/3), negative for
CD117 (0/7), CD34 (0/7), DOG1 (0/4), and S100 (0/5). No mutations were identified on Next-
Generation Sequencing test, and no loss of SDHB immunoreactivity was identified in the
tumor with nuclear pleomorphism. One case was treated with Gleevec because of the
initial diagnosis of GIST. All patients had a follow-up for up to 11 y, with no tumor
recurrence or metastasis reported. Our results suggest that gastric plexiform fibromyx-
oma is rare and may be underrecognized and misinterpreted as GIST duringhology, Immunology, and Laboratory Medicine, Kaiser Permanente Sacramento Medical
6 973 7260; fax: þ001 916 973 7283.
i).
ier Inc. All rights reserved.
l a i e t a l  g a s t r i c p l e x i f o rm fi b r omy x oma 77intraoperative frozen section or preoperative EUS-FNA diagnosis without immunostains
leading to inappropriate treatment.
ª 2019 Elsevier Inc. All rights reserved.Introduction underwent at least partial gastrectomy and had intraoperativeGastrointestinal stromal tumor (GIST) is the most common
primary mesenchymal tumor of the stomach and spans a
clinical spectrum from benign to malignant. GISTs have a
broad morphological spectrum including the most commonly
encountered spindle cell type, the less frequently epithelioid
type, and mixed spindle and epithelial types with multiple
histologic patterns including palisaded-vacuolated, scle-
rosing, discohesive, pseudopapillary, and myxoid patterns.1
The majority of GISTs harbor a KIT (C-Kit) mutation,
whereas a small portion has PDGFRA mutation and SDH
deficiency.1 Immunohistochemically, the majority of GISTs
are positive for C-Kit/CD117 and Dog1 stains and frequently
positive for CD34. Gastric plexiform fibromyxoma (GPF) is a
rare benign mesenchymal neoplasm usually arising in the
gastric antrum and clinically manifesting similar to a GIST.
Only a few cases of GPF have been reported since the first case
described in 2007 by Takahashi et al.2-7 The characteristic
histologic features of GPF include multiple plexiform nodules
containing paucicellular to moderately cellular myxoid,
collagenous, or fibromyxoid stromal components.5 In contrast
to GIST, GPF is negative for C-Kit/CD117, Dog1, and CD34.
So far, the reported GPF cases behave as a benign tumor with
neither recurrence nor metastases after resection. However,
their identification is challenging if their pre and intraoperative
diagnosis is performed without immunostains. Because of their
clinical and morphological similarities to myxoid variant GIST
and the rarity of the disease, we hypothesized that GPF could be
misdiagnosed as GIST during intraoperative frozen sections
diagnosis or preoperative EUS-FNA diagnosis without the use of
immunostains. To test this, we searched the databases of mul-
tiple medical centers across the country for cases with a final
diagnosis of GPF since 2007. A total of seven cases in four major
medical centers were identified. We recorded the diagnoses of
intraoperative frozen sections and preoperative EUS-FNA if
available, final diagnosis and current follow-up, and reviewed all
of the slides including frozen sections, EUS-FNA smears, and
permanent sections with immunostains. The clinical and
radiographical findings and diagnostic pitfalls on correct diag-
nosis of this rare entity are discussed.Materials and methods
Patient selection
Through a multicenter pathology database search for cases
with a diagnosis of GPF from January 2007 toMarch 2018, a total
of seven cases of GPF were identified at Cedars-Sinai Medical
Center,2 University of Florida,2 University of California in Los
Angeles,2 and Washington University in St. Louis.1 The seven
patients include four males and three females with an age
range of 21-79 y (46.1  10.1). Six of the seven patientsfrozen sections (5/6) and/or preoperative EUS-FNA (2/6) without
immunostains (Table). One case (case #7) was recently diag-
nosed on the biopsy of a small polypoid gastric lesion with
immunostains, and no further resection was performed. The
slides of each case were reviewed by at least three pathologists
(at least two from each institution and JL reviewed all of the
cases). The study was approved by the IRB at Cedars-Sinai
Medical Center with approved waiver of the consent.
Immunohistochemistry
Immunostaining for C-Kit/CD117, CD34, DOG1, smooth mus-
cle actin (SMA), Desmin, and S100 was performed in seven
GPFs. Tissue sections (4 mm)were cut from paraffin-embedded
tissue blocks and stained with antibodies against C-Kit/CD117
(Clone YR145; Cell Marque, Rocklin, CA, USA), CD34 (Clone
QBEnd/10, Ventana, Tucson, AZ, USA), DOG1 (Clone K9, Leica,
Chicago, IL, USA), SMA (Clone 1A4, DAKO, Carpenteria, CA,
USA), Desmin (Clone DE-R-11, Ventana, Tucson, AZ, USA), and
S100 (Clone ZO311, DAKO, DAKO, Carpenteria, CA, USA).
Immunohistochemical staining was performed on the Ven-
tana Benchmark Ultra (Ventana, Tucson, AZ, USA). Pretreat-
ment was performed with antigen retrieval method as a
routine procedure. The immunostain intensity was evaluated
with a previously reported scoring system.8,9 The intensity of
membranous and cytoplasmic staining was evaluated as fol-
lows: 1þ, weak; 2þ, moderate; and 3þ, strong. The intensity
was based on comparison with staining of external positive
controls or internal positive controls (mast cells, endothelial
cells, or smooth muscle from the muscularis mucosae).
Next generation sequencing
In case #3, because of the nuclear pleomorphism of the tumor
cells, increased mitotic activity, and the negative SDHB
immunostain, Next-Generation Sequencing (NGS) was per-
formed in thisGPF. The area of tumorwas localizedonanHand
E slide and microdissected. Genomic DNA extracted from the
tissue was sequenced using the GatorSeq NGS Panel and
sequenced on the Illumina NextSeq to high uniform depth
(targeting500xcoveragebynon-PCRduplicate readpairswith>
99% of exons at coverage > 100). The following genes were
assayed: ABL1; AKT1; ALK; ASXL1; BAALC; BCOR; BCR; BRAF;
BRINP3; CBFB; CEBPA; CRLF2; CTNNB1; DDR2; DEK; DNMT3A;
EGFR; ERBB2; ERG; ETV6; EZH2; FBXW7; FGFR1; FGFR2; FLT3;
GNA11; GNAQ; HOXA9; HRAS; IDH1; IDH2; JAK2; KIT; KMT2A;
KRAS; MAP2K1; MECOM; MET; MKL1; MLLT3; MN1; MPL; MYC;
MYH11; NF1; NOTCH1; NPM1; NRAS; NUP214; PDGFRA; PHF6;
PIK3CA; PML; PTEN; PTPN11; RAD21; RARA; RBM15; RET; RPN1;
RUNX1; RUNX1T1; SF3B1; SMAD4; SMC1A; SMC3; SMO; SRSF2;
STAG2; TET2; TP53; TSC1; U2AF1; U2AF2; WT1; ZRSR2; FLT3,
NUP214; ALK; ERBB2; ASXL1; PML; TP53; KMT2A; MKL1; BCR;
and PDGFRA. Sequence data were processed using a
Table e Clinicopathological characteristics of gastric plexiform fibromyxomas.
Case # Age (y) Gender Location Size (cm) FS/FNA IHC Follow-up
C-kit CD34 DOG1 SMA Des S100
1 21 F Body 17.0 GIST - - n/a þ - - 4 y
2 42 F Antrum 8.0 GIST - - - n/a - - 4 y
3 79 F Antrum 3.7 GIST - - - þ þ/ - 1 y
4 33 M Antrum 3.2 GIST - - n/a þ þ/ - 11 y
5 60 M Antrum 1.6 GIST - - - þ þ - 1 y
6 77 M Body 3.2 GIST - - - þ n/a n/a 2 y
7 45 M Antrum 0.3 n/a - - - þ n/a n/a .2 y
FS ¼ frozen section; FNA ¼ fine needle aspiration.
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accurately detect base substitutions and insertions/deletions.
Annotated reports were generated using GenomeOncology
software and database. Human genome version hg19was used
as the reference and was downloaded from http://ftp.
broadinstitute.org/bundle/2.8/hg19. The mutation nomencla-
turewasbasedon theconvention recommendedby theHuman
Genome Variation Society (http://www.hgvs.org/mutnomen/).Results
Clinical features of GPFs and 6/6 initially misdiagnosed as
GIST
The seven patients included four female and three male,
and they were 21 to 79 (46.1  10.1) y. All cases showed aFig. 1 e Gastric plexiform fibromyxoma case 1. (A), Axial CT sca
enhancing rim involving gastric body; (B and C), frozen section
present in the muscularis propria with arborizing vascular arch
section of the tumor showing similar features and overlying oxy
right, 4003). (Color version of figure is available online.)unilocular lesion arising from antrum5 or body.2 The tumor
sizes ranged from 0.3 to 17 cm in greatest dimension. In-
formation on radiographic studies of these tumors is
limited. In case #1, the abdominal computed tomography
(CT) scans showed a 17 cm hypoattenuating mass with a
slightly enhanced rim in the left upper quadrant, radiolog-
ically worrisome for a mucinous malignancy from a gastric
origin (Fig. 1A). The mass abutted and mildly displaced the
pancreas from neck to tail, and the mass was in close con-
tact with the greater curvature of the stomach and the colon
splenic flexure. This patient underwent gastrectomy, distal
pancreatectomy, splenectomy, and partial colectomy.
Endoscopically, the lesions showed a polypoid mass in the
stomach. Six of the seven cases had intraoperative frozen
sections and/or preoperative EUS-FNA. The cytology ex-
amination of these cases showed spindle cells with mark-
edly elongated light blue cytoplasm and light blue myxoidn showing a 17 cm hypoattenuating tumor (T) with slightly
showing multiple flexiform myxoid tumor nodules (T)
itecture and intracytoplasmic vacuoles; (D), Permanent
ntic mucosa (O) (H and E stain: B and D left, 403; C, 2003; D
Fig. 2 e Immunoreactivity of GPF case 1 showing that the tumor cells are negative for CD117 (A), CD34 (B), focally positive for
SMA (C), and negative for Desmin (D) (A-D, 2003). (Color version of figure is available online.)
l a i e t a l  g a s t r i c p l e x i f o rm fi b r omy x oma 79stroma in Papanicolaou and Diff-Quikestained material.
The tumor cells displayed oval to moderately elongated
nuclei with a fine homogenous chromatin and lack nucleoli.
Most nuclei ends were rounded; the tumor nuclei did not
display tapered and irregular ends. These cells were orga-
nized in bundles; and their nuclei showed a parallelFig. 3 e Gastric plexiform fibromyxoma case 2. (A), Endoscopic
ulceration; (B), FNA showing cytological bland spindle cell prolif
showing cytological bland spindle cell proliferation with low ce
4003). (Color version of figure is available online.)streaming pattern. These six cases were preoperatively or
intraoperatively interpreted as GIST or probable GIST
(Table). Case #7 was a recent biopsy case of an antral
polypoid lesion. Follow-up was available on all cases,
ranging from less than a year up to 11 y. No tumor recur-
rence or metastases were identified (Table).appearance showing an antral mass with surface erosion/
eration (Pap smear, 4003); (C and D), Resection of the mass
llularity in the myxoid stroma (H and E stain: C, 1003; D,
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Histologically, the tumors exhibited the typical described
histology, which was characterized by a plexiform growth
pattern with nodules in the muscularis propria (Fig. 1B),
infiltrative borders, and arborizing vascular architecture on
frozen section (Fig. 1B and C). The tumors were composed of a
rich myxoid stroma, and the majority (6/7) showed cytologi-
cally bland uniform spindle cells without mitotic figures
identified (Fig. 1D). Two of seven cases showed gastric body
with overlying oxyntic mucosa (Fig. 1D left) as the origin.
Immunostains were performed in all the cases (Fig. 2). They
were focally positive for SMA (6/6), focally andweakly positive
for desmin (3/6) and caldesmon (2/3), negative for CD117 (0/7),
CD34 (0/7), DOG1 (0/4), and S100 (0/5). SDHB immunoreactivity
was intact in 2 of 2. Six of the seven cases were morphologi-
cally benign and showed a low Ki-67 proliferative index (< 2%)
including the 17 cm one. More histopathology with matched
FNA cytopathology and endoscopic experiences of GPFs were
shown in Figure 3.
One unusual case of GPF with a synchronous GIST
Case #3 was unusual. In this patient, a 3.7 cm GPF and a
synchronous separate and isolated 0.7 cm GIST were identi-
fied from the partial gastrectomy specimen. The GPF showed
low to moderate cellularity arising from antrum (Fig. 4A) with
nuclear pleomorphism and three mitotic figures per 10 high-
power fields (Fig. 4B), but no lymphovascular invasion, peri-
neural invasion, or metastasis was identified. The GPF was
negative for C-Kit/CD117 (Fig. 4C), DOG1 (Fig. 4D left), CD34,
and S100 but positive for SMA and focally positive for desmin.Fig. 4 e Gastric plexiform fibromyxoma case 3. (A and B), H and
involvement by plexiform myxoid tumor with nuclear pleomor
Immunohistochemistry showing the tumor cells are negative fo
in a 5 mm2 area (D right) (A, 403; B-D, 4003). (Color version ofSDHB immunoreactivitywas intact in the GPF tumor cells. The
Ki-67 proliferative index was 30%. Phospho-histone H3 high-
lighted six positive cells in a 5 mm2 area (Fig. 4D right). In
contrast, the separate and incidental GIST was cytological
blandwith calcification and typical spindle cell morphology of
GIST with no mitotic figures identified (Fig. 5A and B) and
strong and diffuse positivity for C-Kit/CD117 (Fig. 5C), DOG1
(Fig. 5D), and CD34. The ki-67 proliferative index was 1%. NGS
was performed and no pathologic mutations or variants were
identified in the GPF. This was a consultation case and the
patient was treated with Gleevec for the initial diagnosis of
GIST at an outside institution. During clinical follow-up, at the
time of preparation of this article, the patient had cardiac
dysfunction and sepsis, but no tumor recurrence or metas-
tasis was identified.Discussion
GPF is a rarely reported benign mesenchymal neoplasm seen
in the gastric antrum. Because of clinical and morphological
similarity to myxoid variant of GIST and the rarity of the dis-
ease, we tested the hypothesis that GPF could be mis-
diagnosed as GIST during intraoperative frozen section
examination and/or preoperative EUS-FNA diagnosis if
immunostains were not employed. The findings in this case
series include: 1) 100% (6/6) of GPF were misinterpreted as
GIST in preoperative EUS-FNA and/or during intraoperative
frozen section; 2) up to 30% of GPF may originate from the
gastric body; 3) Rarely, GPF can have unusual histology such as
nuclear pleomorphism and synchronously coexist with GIST
in the same gastrectomy specimen. These are the diagnosticEestained section of the tumor showing transmural
phism and increased mitotic figures (Arrows); (C and D),
r CD117 (C), DOG1 (D left). PHH3 highlights six positive cells
figure is available online.)
Fig. 5 e Synchronous GIST in case 3. (A and B), H and Eestained section of the tumor showing a spindle cell neoplasm with
no mitotic activity; (C and D), Immunohistochemistry showing the tumor cells are positive for CD117 (C) and DOG1 (D) (A,
403; B-D, 4003). (Color version of figure is available online.)
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management.
Plexiform fibromyxoma is a distinctive benign gastric
neoplasm that should be separated from GIST, nerve sheath
tumors, and other fibromyxoid/spindle cell neoplasms.3 His-
tologically, typical GPF is a plexiform intramural growth with
multiplemicronodules containing paucicellular tomoderately
cellular myxoid, collagenous, and fibromyxoid neoplastic
stromal elements. A prominent plexiform pattern is typically
present. The tumor cells varied from oval to spindled and had
limited atypia and mitotic activity < 5/50 high-power fields.3,4
In review of our cases, the typical histologic patterns were
present on the frozen sections. Misinterpretation of these
tumors as GISTs is likely a result of lack of awareness of this
entity and the fact that GIST is a farmore common tumorwith
similar morphology. In contrast to GIST, GPF is consistently
negative for c-Kit (CD117), DOG1, CD34, desmin, and S100
protein on immunostains.3
On fine needle aspiration (FNA) material, the GPF cyto-
morphology is strikingly similar to GIST but there are some
subtle differences. GPF tumors show markedly elongated
spindle cells with oval to elongated streaming nuclei and
myxoid background. In cytology specimens, the differential
diagnosis includes smooth muscle proliferations, GIST, and
tumors of neural origin such as schwannoma and neurofi-
bromas. Aspirates from smooth muscle proliferations such as
leiomyoma show tridimensional clusters of cells with spindle
morphology; most leiomyoma cells show with oval to elon-
gated nuclei with rounded ends. Leiomyosarcomas are iden-
tified by their nuclear pleomorphism and mitoses. Smooth
muscle tumor cells express SMA, desmin, and h-caldesmon.
GIST aspirates show also tridimensional clusters of spindle
cells or epithelioid cells with cohesive and loose patterns;parallel and streaming arrangements of cells and nuclei may
be seen. The nuclei may show oval to elongated irregular-
shaped nuclei with a fine to coarse chromatin; some tumors
may show stripped nuclei. GIST cells cytoplasm may show a
distinctive delicate fibrillary appearance with wispy cyto-
plasmic extensions. Bipolar cytoplasmic processes as well as
perinuclear cytoplasmic vacuoles may be seen. In addition,
GIST aspirates may show focally myxoid background and
loosely fibrillary and pink to magenta stromal material on
Romanoswky-type stains. GIST cells express c-kit (CD117),
DOG1, and CD34.1 Neural origin tumors show spindle cells
with elongated nuclei with tapered to irregular pointed ends
(wavy to fishhook-like). Schwannomas may show nuclear
palisading and clear patterns identifiable as Verocay bodies.
Neurofibromas may show distinct spindled fibroblasts and
myxoid stroma. Both neural tumors are positive for S100. In
two of our cases, preoperative EUS-FNA aspiration was per-
formed with smears for cytology assessment. However, no
immunostainswere performed on the cell blocks or cell blocks
may not have been available. The cytopathologic diagnosis
was spindle cell proliferation consistent with GIST because of
a clinical impression of GIST in these two cases. One of the
two also had intraoperative frozen section diagnosis of GIST.
Therefore, utilization of a panel of immunomarkers including
CD117, CD34, DOG1, SMA, Desmin, and S100 should be per-
formed on the cell blocks of spindle cell specimens from EUS-
FNA of the stomach for a definite diagnosis of GIST.
Plexiform fibromyxoma is a distinctive mesenchymal
neoplasm that occurs almost exclusively in the gastric
antrum/pylorus region.1-6 In our case series, two of seven
patients had the GPF in the gastric body by imaging and
endoscopic findings and histology confirmed overlying oxy-
ntic mucosa inmultiple sections of these two GPFs. Therefore,
82 j o u r n a l o f s u r g i c a l r e s e a r c h  j u l y 2 0 1 9 ( 2 3 9 ) 7 6e8 2GPF can also occur in the gastric body. This is consistent with
another recently reported case of a histologically confirmed
GPF with imaging findings of a cystic-solid well-circumscribed
extraluminal mass located in the posterior wall of the gastric
upper body.7
Reportedly, no KIT or platelet-derived growth factor re-
ceptor alpha (PDGFRa) mutations were identified in the three
examined cases.3 A recent study alsomentioned that the gene
glioma-associated oncogene homologue 1 (GLI1) may be pre-
sent in a subgroup of these tumors.10 In our series, we had an
unusual consultation case that has nuclear pleomorphism,
increasedmitotic activity with threemitotic figures in 10 high-
power field with six PHH3 positive cells in 5 mm2 area, and
30% of Ki-67 proliferation index as well as a synchronous
0.7 cm GIST. This tumor did not show lymphovascular inva-
sion or perineural invasion. The patient was previously
treated with Gleevec for initial diagnosis of GIST and experi-
enced some side effects. Currently, the patient has been
followed-up for 1 y since her diagnosis and showed no evi-
dence of tumor recurrence or metastasis. Because of its un-
usual morphology, we performed next generation sequencing
for this GPF, but no C-kit, PDGFRA, or other mutations are
identified. We also performed immunohistochemistry for
SDHB to rule out a small possibility of SDH deficient-GIST, but
the tumor showed intact expression of SDHB. To the best of
our knowledge, this is the first documented case with coex-
istence of GPF and GIST.
In summary, our case series of GPF demonstrated that this
entity can be underrecognized or misinterpreted without the
pathologists’ awareness of this entity and performing
adequate immunostains.Misinterpreting GPF as GIST can lead
to inappropriate treatment including unnecessary surgery
and/or chemotherapy such as imatinib (Gleevec), which is an
expensive and, in the case of GPF, ineffective treatment with a
potential for adverse side effects. In addition to the originally
report predilection of this tumor in the antrum, it can also
arise from the body. Nomalignant cases have previously been
reported in the English literature. One of our cases with nu-
clear polymorphism, increasedmitotic activity, and high Ki-67
index is still being followed-up, yet shows no recurrence or
metastasis to date.
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